Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
Curr Opin Immunol. 2011 Jun;23(3):383-90. doi: 10.1016/j.coi.2011.04.003. Epub 2011 Apr 27.
Although antibodies can be elicited by HIV-1 infection or immunization, those that are broadly neutralizing (bnAbs) are undetectable in most individuals, and when they do arise in HIV-1 infection, only do so years after transmission. Until recently, the reasons for difficulty in inducing such bnAbs have been obscure. Recent technological advances in isolating bnAbs from rare patients have increased our knowledge of their specificities and features, and along with gene-targeting studies, have also begun uncovering evidence of immunoregulatory roadblocks preventing their induction. One crucial avenue towards developing an effective HIV-1 vaccine is to harness this emerging information into the rational design of immunogens and formulation of adjuvants, such that structural and immunological hurdles to routinely eliciting bnAbs can be overcome.
虽然 HIV-1 感染或免疫可以引发抗体,但大多数人无法产生广泛中和抗体(bnAbs),而在 HIV-1 感染中产生的 bnAbs 也只是在感染后数年才出现。直到最近,诱导产生此类 bnAbs 的困难原因还不清楚。最近从少数患者中分离 bnAbs 的技术进步增加了我们对其特异性和特征的了解,并且与基因靶向研究一起,也开始揭示出阻止其诱导的免疫调节障碍的证据。开发有效 HIV-1 疫苗的一个关键途径是将这些新出现的信息应用于免疫原的合理设计和佐剂的配方,从而克服常规诱导 bnAbs 的结构和免疫学障碍。